文献速递前列腺癌

挽救性高强度聚焦超声(HIFU)治疗放疗失败后局部复发性前列腺癌:418例患者的多中心分析

Salvage high-intensity focused ultrasound (HIFU) for locally recurrent prostate cancer after failed radiation therapy: Multi-institutional analysis of 418 patients.
PubMed 文献 · BJU Int · 2017-03-10

这项多中心回顾性研究纳入9个中心1995至2009年间418例外照射放疗(EBRT)后局部复发的前列腺癌患者,接受挽救性高强度聚焦超声(S-HIFU)治疗。7年总生存率、癌症特异性生存率和无转移生存率分别为72%、82%和81%;5年生化无失败生存率(bFFS)按EBRT前风险分组为低危58%、中危51%、高危36%。作者结论认为S-HIFU与7年癌症特异性生存率和无转移生存率超过80%相关,但伴随显著并发症,并建议在EBRT失败后早期启动S-HIFU。

要点

  • 7年总生存率72%、癌症特异性生存率82%、无转移生存率81%。
  • 5年bFFS按EBRT前风险:低危58%、中危51%、高危36%。
  • 5年bFFS按S-HIFU前PSA:≤4 ng/mL为67%、4-10 ng/mL为42%、≥10 ng/mL为22%。

核心结论

  • S-HIFU治疗EBRT失败后局部复发性前列腺癌与7年癌症特异性生存率和无转移生存率超过80%相关,但伴随显著并发症。
  • 作者建议在EBRT失败后早期启动S-HIFU。

研究设计与样本

  • 回顾性研究,纳入9个中心1995至2009年间EBRT后局部复发并接受S-HIFU治疗的患者。
  • 共418例患者,平均(标准差)随访3.5(2.5)年,平均(标准差)年龄68.6(5.8)岁,S-HIFU前PSA水平6.8(7.8)ng/mL。
  • 生化失败采用Phoenix定义(PSA最低值+2 ng/mL),次要终点包括进展至转移和癌症特异性死亡,采用Kaplan-Meier分析总生存、癌症特异性生存和无转移生存。

主要发现

  • S-HIFU后中位PSA最低值为0.19 ng/mL。
  • 7年总生存率、癌症特异性生存率和无转移生存率分别为72%、82%和81%。
  • 5年bFFS按EBRT前风险分组:低危58%、中危51%、高危36%。
  • 5年bFFS按S-HIFU前PSA分组:≤4 ng/mL为67%、4-10 ng/mL为42%、≥10 ng/mL为22%。
  • 引入特定放疗后参数后并发症发生率下降:尿失禁(II级或III级)从32%降至19%(P=0.002);膀胱出口梗阻或狭窄从30%降至15%(P=0.003);直肠尿道瘘从9%降至0.6%(P<0.001)。

临床怎么用

  • 作者建议在EBRT失败后早期启动S-HIFU。

局限性

  • 研究局限性包括为来自登记数据库的回顾性分析且无对照组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To report the oncological outcome of salvage high-intensity focused ultrasound (S-HIFU) for locally recurrent prostate cancer after external beam radiotherapy (EBRT) from a multicentre database. PATIENTS AND METHODS: This retrospective study comprises patients from nine centres with local recurrent disease after EBRT treated with S-HIFU from 1995 to 2009. The biochemical failure-free survival (bFFS) rate was based on the 'Phoenix' definition (PSA nadir + 2 ng/mL). Secondary endpoints included progression to metastasis and cancer-specific death. Kaplan-Meier analysis was performed examining overall (OS), cancer-specific (CSS) and metastasis-free survival (MFS). Adverse events and quality of life status are reported. RESULTS: In all, 418 patients with a mean (SD) follow-up of 3.5 (2.5) years were included. The mean (SD) age was 68.6 (5.8) years and the PSA level before S-HIFU was 6.8 (7.8) ng/mL. The median PSA nadir after S-HIFU was 0.19 ng/mL. The OS, CSS and MFS rates at 7 years were 72%, 82% and 81%, respectively. At 5 years the bFFS rate was 58%, 51% and 36% for pre-EBRT low-, intermediate- and high-risk patients, respectively. The 5-year bFFS rate was 67%, 42% and 22% for pre-S-HIFU PSA level ≤4, 4-10 and ≥10 ng/mL, respectively. Complication rates decreased after the introduction of specific post-RT parameters: incontinence (grade II or III) from 32% to 19% (P = 0.002); bladder outlet obstruction or stenosis from 30% to 15% (P = 0.003); recto-urethral fistula decreased from 9% to 0.6% (P < 0.001). Study limitations include being a retrospective analysis from a registry with no control group. CONCLUSION: S-HIFU for locally recurrent prostate cancer after failed EBRT is associated with 7-year CSS and MFS rates of >80% at a price of significant morbidity. S-HIFU should be initiated early following EBRT failure.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Crouzet S, Blana A, Murat FJ, et al. Salvage high-intensity focused ultrasound (HIFU) for locally recurrent prostate cancer after failed radiation therapy: Multi-institutional analysis of 418 patients. BJU Int. 2017. PMID: 28063191. doi:10.1111/bju.13766

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。